A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
CONCLUSIONS: For PD patients with erythropoietin hyporesponsiveness, roxadustat can significantly improve renal anemia. The efficacy of roxadustat in improving renal anemia was not affected by baseline levels of hs-CRP0 and iPTH.PMID:38649158 | DOI:10.3904/kjim.2023.520
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Jie Liu Shuang Li Fan Yang Tianyu Li Rui Li Yousuf Waheed Chen Meng Shulin Li Kun Liu Yanshan Tong Haisheng Xu Chuankuo Tian Xinglei Zhou Source Type: research
More News: Anemia | Brain | Cholesterol | Dialysis | Hormones | Internal Medicine | Iron | Men | Neurology | Peritoneal Dialysis | Statin Therapy | Study